Table 3.
Comparison of Mean 3-Year Percent Change in BMD in ZOL Versus Placebo for APR+ Group and for APR− Group
| Change in BMD parameter | APR + |
APR− |
p for interaction | ||||
|---|---|---|---|---|---|---|---|
| ZOL mean (95% CI) | Placebo mean (95% CI) | Difference mean (95% CI) | ZOL mean (95% CI) | Placebo mean (95% CI) | Difference mean (95% CI) | ||
| Change in FN BMD | n = 1378 | n = 368 | n = 1689 | n = 2715 | |||
| Unadjusted | 4.1% (3.8, 4.4) | −0.6% (−1.2, 0.1) | 4.6% (4.0, 5.3) | 4.1% (3.8, 4.4) | −1.0% (−1.2, −0.8) | 5.1% (4.7, 5.5) | 0.22 |
| Adjusteda | 4.1% (3.7, 4.4) | -0.5% (−1.1, 0.1) | 4.6% (3.9, 5.2) | 4.1% (3.8, 4.4) | −1.0% (−1.2, −0.8) | 5.1% (4.7, 5.5) | 0.12 |
| Change in TH BMD | n = 1377 | n = 368 | n = 1684 | n = 2709 | |||
| Unadjusted | 4.4% (4.2, 4.7) | −1.3% (−1.9, −0.7) | 5.7% (5.1, 6.3) | 4.3% (4.0, 4.5) | −1.7% (−1.9, −1.5) | 6.0% (5.7, 6.3) | 0.39 |
| Adjusteda | 4.4% (4.1, 4.6) | −1.2% (−1.7, −0.7) | 5.6% (5.0, 6.2) | 4.3% (4.0, 4.5) | −1.8% (−2.0, −1.6) | 6.1% (5.7, 6.4) | 0.14 |
| Change in LS BMD | n = 91 | n = 37 | n = 137 | n = 175 | |||
| Unadjusted | 7.1% (6.0, 8.2) | 1.7% (0.2, 3.2) | 5.4% (3.5, 7.4) | 8.1% (7.2, 8.9) | 0.9% (0.0, 1.8) | 7.2% (5.9, 8.4) | 0.16 |
| Adjusteda | 7.3% (0.5, 6.3) | 1.0% (−0.6, 2.7) | 6.2% (4.3, 8.1) | 8.1% (7.2, 9.0) | 0.9% (0.0, 1.7) | 7.2% (6.0, 8.4) | 0.38 |
APR = acute-phase reaction; BMD = bone mineral density; CI = confidence interval; FN = femoral neck; LS = lumbar spine; TH = total hip; ZOL = zoledronic acid.
a
Adjusted for race (Asian or non-Asian), age, prior bisphosphonate usage, active back pain, diabetes, femoral neck BMD, number of prevalent vertebral fractures, creatinine clearance, alkaline phosphatase.